Form 4: HilleVax Director Julie Gerberding Granted Over 17,000 Restricted Stock Units

HilleVax, Inc. Director Julie L. Gerberding was granted 17,199 Restricted Stock Units (RSUs) as part of the company's Non-Employee Director Compensation Program.

Summary

• Julie L. Gerberding, a Director of HilleVax, Inc. (HLVX), acquired 17,199 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on June 23, 2025, with the RSUs granted at a price of $0.00.
• Following this grant, Ms. Gerberding beneficially owns a total of 59,224 shares of Common Stock.
• The RSUs are set to vest 100% on the first anniversary of the grant date (June 23, 2026) or upon a Change in Control, provided the director continues in service.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new operational or financial developments beyond standard compensation practices.

Positives

• The grant of Restricted Stock Units to a non-employee director aligns the director's interests with those of the shareholders, incentivizing long-term performance.
• The compensation is part of a pre-existing Non-Employee Director Compensation Program, indicating a structured approach to governance and executive incentives.

Future Outlook

The granted Restricted Stock Units are subject to future vesting conditions, specifically on the first anniversary of the grant date (June 23, 2026) or upon a Change in Control, contingent on the director's continued service.

Industry Context

The grant of Restricted Stock Units to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain experienced board members and align their interests with long-term company performance.

Comparison to Industry Standards

• Equity compensation, such as RSU grants, for non-employee directors is a standard practice across publicly traded companies, particularly in the biotech sector, to incentivize long-term commitment and align interests with shareholders.
• The vesting schedule, typically over one year or upon a change of control, is also consistent with common industry benchmarks for director equity awards.

Corporate Governance

Related Party Transactions

• Grant of 17,199 Restricted Stock Units to Julie L. Gerberding, a Director of HilleVax, Inc., as part of her compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact mentioned, but a well-compensated board can contribute to overall company stability and success.

Next Steps

• The granted Restricted Stock Units will vest on June 23, 2026, or earlier upon a Change in Control, subject to the director's continued service.

Key Dates

Keywords

HilleVax, HLVX, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Corporate Governance